person · Reporting owner
Williams Brinkley Ruth
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Natera, Inc.NTRA · Entity 2635 | Director | April 24, 2026 | April 29, 2026 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Natera, Inc.
Report date April 24, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,475 |
Reported balance
After 2026-04-24 transaction · row 1
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 86 · Balance 5,475 F1: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $17,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $17,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Travere Therapeutics, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,750 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 4,000 · Balance 29,750 F1: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2: The equity award vests over a one year period. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.26 · Expires 2036-05-19 | Direct | 12,000 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Grant · Acquired 12,000 · Balance 12,000 F1: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2: The equity award vests over a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
F2: The equity award vests over a one year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001344381-26-000004 · form4-05212026_050518.xml · derivative · entry 2 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001344381-26-000004 · form4-05212026_050518.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,750 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 24, 2026 Filed Apr 29, 2026 00:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 86 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001344381-26-000002 · form4-04282026_080405.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,475 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $17,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 30, 2026 Filed Feb 4, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 73 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001344381-26-000001 · form4-02032026_080213.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,389 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $17,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| October 31, 2025 Filed Nov 5, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 97 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001344381-25-000005 · form4-11042025_091112.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,316 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $17,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020519 · form4-07292025_090712.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,219 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $17,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 27, 2025 Filed Jul 2, 2025 01:15 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 2,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-018840 · form4-07012025_090714.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,107 F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2026. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001415889-25-013504 · form4-05162025_070518.xml · derivative · entry 2 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-05-15 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013504 · form4-05162025_070518.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,750 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 2,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019069 · form4-07022024_090713.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,964 F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2025. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:06 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001415889-24-012852 · form4-05102024_040555.xml · derivative · entry 2 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2034-05-07 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:06 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012852 · form4-05102024_040555.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,250 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 515 | $25.03 Strike: $38.26 | $12,890.45 |
DisclosureSEC source: 0001415889-23-014639 · form4-10312023_091003.xml · derivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515 Underlying: Common Stock · 515 shares Expires 2033-10-26 F1 · shares: The option was issued to the Reporting Person in lieu of quarterly retainer fees of $14,375 for service on the Issuer's Board of Directors. F2 · derivative.exercise_date: The option shares are fully vested and may be exercised at any time. Read SEC document |
| July 28, 2023 Filed Aug 2, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 428 | $29.68 Strike: $45.88 | $12,703.04 |
DisclosureSEC source: 0001415889-23-011689 · form4-08012023_090811.xml · derivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428 Underlying: Common Stock · 428 shares Expires 2033-07-27 F1 · shares: The option was issued to the Reporting Person in lieu of pro-rated quarterly retainer fees of $13,427.20 for service on the Issuer's Board of Directors. F2 · derivative.exercise_date: The option shares are fully vested and may be exercised at any time. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 13,500 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-23-030963 · doc4.xml · derivative · entry 2 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2033-05-16 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030963 · doc4.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,750 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 14, 2023 Filed Apr 19, 2023 00:10 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 120 | $32.88 Strike: $51.40 | $3,945.60 |
DisclosureSEC source: 0001415889-23-006661 · form4-04182023_080423.xml · derivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120 Underlying: Common Stock · 120 shares Expires 2033-04-13 F1 · shares: The option was issued to the Reporting Person in lieu of pro-rated quarterly retainer fees of $4,230 for service on the Issuer's Board of Directors. F2 · derivative.exercise_date: The option shares are fully vested and may be exercised at any time. Read SEC document |
| March 24, 2023 Filed Mar 29, 2023 01:45 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 10,767 | $0.00 Strike: $56.65 | $0.00 |
DisclosureSEC source: 0001415889-23-005536 · form4-03282023_090302.xml · derivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,767 Underlying: Common Stock · 10,767 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option shares shall vest in three (3) equal annual installments beginning on March 2, 2024. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:42 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001209191-22-028704 · doc4.xml · derivative · entry 2 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-05-10 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:42 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028704 · doc4.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:16 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $23.61 | $0.00 |
DisclosureSEC source: 0001209191-21-056459 · doc4.xml · derivative · entry 2 Brinkley Ruth Williams · CIK 0001344381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2031-09-13 F1 · derivative.exercise_date: One-third of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:16 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056459 · doc4.xml · nonDerivative · entry 1 Brinkley Ruth Williams · CIK 0001344381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.